National Post: Calgary-based biotech firm specializes in instructing cells to fight complex diseases

Recent Posts

Rakovina Therapeutics has obtained exclusive rights to compounds from the Enki™ platform and the option to license validated drug candidates

ZUNVEYL targets symptoms to provide long-lasting benefits to cognitive and global function and the ability to perform daily activities.

FDA recommends additional revised primary symptom-based endpoints Revive to provide amended statistical analysis plan to support...